Zaidi

BACKGROUND

18 Lead Plaintiff Ralph Martinez (“Martinez”), on behalf of himself and other investors who 19 acquired Adamas securities between August 8, 2017 and March 4, 2019 (the “Class Period”), 20 alleges Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and 21 Rule 10b-5 promulgated thereunder. 22 On October 8, 2021, the Court granted Defendants’ motion to dismiss Martinez’s first amended complaint (“FAC”), with leave to amend. (Dkt. No. 79, “Order”.) As discussed in that 24 Order, Adamas is a pharmaceutical company that specializes in developing treatments for chronic

26 The Court refers to Went, Merriweather, and King as the “Individual Defendants.” 27 Martinez amended the Class Period, which originally ran through September 30, 2019 and neurological disorders, including Parkinson’s disease. Went acted as Adamas’ Chief Executive Officer and its Chairman of the Board of Directors from its founding in 2000 to September 16, 2019, when he transitioned to a strategic advisory role. Merriweather acted as Adamas’ Chief Financial Officer from June 2017 until December 31, 2019, when he retired. King acted as 5…